Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.6 |
mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |